Malnutrition frequently affects patients with alcoholic liver disease (ALD), with important impacts on disease prognosis. Sarcopenia, the clinical phenotype of malnutrition characterized by skeletal muscle loss, is the major component responsible for adverse events in this population. The aim of this study is to assess the use of ultrasound (US) skeletal muscle performance in stratifying ALD disease severity. We recruited 43 patients with ALD and divided them into two groups: alcoholic hepatitis (AH) and alcoholic cirrhosis (AC). We evaluated disease-specific clinical and biological parameters and their relation to US Rectus Femoris muscle (RFM) measurements, including RFM thickness, stiffness (RFMS) and echogenicity (RFE). A thirty-seconds chairs stand test (30sCST) was used as the sarcopenia surrogate test. RMF thickness correlated with platelet count and serum albumin (p < 0.001). Both RFM and RFMS correlated with disease severity (p < 0.001) and 30sCST (p < 0.001, p = 0.002). Patients with AH had more severe US muscle abnormalities compared to AC (RFMS 1.78 m/s vs. 1.35 m/s, p = 0.001) and the highest prevalence of RFE (χ2 = 8.652, p = 0.003). Rectus Femoris US assessment could represent a reliable tool in the diagnosis and severity stratification of ALD-induced sarcopenia.
17 April 2025 in Romanian Journal of Internal Medicine
Alcohol-related liver disease (ALD) is still to this date one of the leading causes of chronic liver disease globally. ALD comprises a wide disease spectrum, from the benign liver steatosis, to the life-threatening inflammatory acute phenotype of alcoholic hepatitis (AH) and ultimately, advanced liver fibrosis and cirrhosis. AH represents an acute inflammatory liver condition caused by prolonged high quantities of alcohol intake. Disease outcome varies from mild to severe, with systemic implication and high mortality. Although the pathogenesis has been extensively studied over the years, little progress has been made regarding therapeutic options. In over 50 years, steroid treatment is still the cornerstone therapeutic option, albeit having multiple limitations and a low success rate. On the other hand, important progress has been made regarding disease management and severity stratification with the implementation of different prognostic score. Although highly prevalent, AH still has many unmet needs, with a growing necessity for novel non-invasive diagnosis, prognosis biomarkers and impactful treatment options.
Background: Alcohol-associated hepatitis (AH) is an acute inflammatory phenotype of alcohol-associated liver disease associated with substantial short-term mortality. Established clinical scores quantify disease severity but do not directly characterize liver tissue mechanics. Ultrasound-derived viscosity-related measurements may provide complementary, non-invasive information on viscoelastic tissue behavior, although their biological determinants remain incompletely defined. Objective: We aimed to evaluate the association between liver viscosity and AH through the Sound Touch Visco-elastography Imaging (STVi) parameter and inflammatory, biochemical, and MDF-defined severity measures, and to explore its discriminatory performance. Methods: This prospective, single-center, cross-sectional pilot study included 62 patients with clinically diagnosed AH and 30 healthy volunteers. Participants underwent multiparametric ultrasound assessment using the Resona A20 platform with STVi, liver stiffness measurement, and attenuation imaging. Results: The viscosity-related parameter was higher in patients with AH than in healthy volunteers and was associated with liver stiffness, inflammatory markers, and MDF-defined severity. The exploratory AH-versus-healthy comparison yielded an AUC of 0.873 (95% CI, 0.797–0.934). Within the AH cohort, 28 patients had severe AH (MDF ≥ 32) and 34 had non-severe AH. For MDF-defined severe AH, the AUC was 0.863 (bootstrap 95% CI, 0.756–0.955). At the Youden-derived cutoff of 2.8 Pa·s, sensitivity was 78.6% and specificity was 94.1%. Conclusions: STVi provides a model-derived, platform-dependent viscosity-related parameter associated with inflammatory measures and clinical severity in AH. These preliminary findings suggest that liver viscosity imaging may represent a valuable new avenue for the non-invasive assessment of AH. However, standardized acquisition, longitudinal assessment, histological correlation, and external validation are required before clinical implementation.